Guiding chemotherapy treatment decisions in patients with early-stage breast cancer

This activity is older than 12 months.

This patient case has been developed with the assistance of Prof. Joseph Gligorov (Professor of Medical Oncology at Sorbonne University and Medical Practitioner at the Medical Oncology Department of Tenon Hospital, Paris, France). This activity was supported by Exact Sciences.

The information presented is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of their professional license, experience, and knowledge of the individual patient.

For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling. Please note that products may have different product labeling according to geographical location. Within Europe, full prescribing information is available from the European Medicines Agency (EMA – www.ema.europa.eu).

All characters and events depicted in this patient case simulation are entirely fictitious. Any similarity to actual events or persons, living or dead, is purely coincidental. This activity is intended only for healthcare professionals (HCPs) registered to practise in any territory excluding the USA. To proceed, please confirm that you are a HCP practising in a territory other than the USA.

Modules

• Utility of the 21-gene assay (Oncotype DX®) to guide treatment decisions in a postmenopausal woman with node-positive breast cancer